Latigo Biotherapeutics

“Latigo Biotherapeutics 'Raised $345.6 million in its IPO'”

“Latigo Biotherapeutics...raised $346m in its IPO. It priced 19.2m shares at $18, versus plans to offer 16m at $16-$18.”

“Blue Owl Capital-backed biotech company Latigo Biotherapeutics, which develops pain medicines, is seeking to raise up to $288 million in its IPO.”

“Latigo Biotherapeutics, a Thousand Oaks, Calif.-based developer of non-opioid pain management drugs, set IPO terms to 16m shares at $16-$18.”